Cutaneous Myeloma and Bortezomib

Annals of Hematology - Germany
doi 10.1007/s00277-009-0786-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Nelfinavir Augments Proteasome Inhibition by Bortezomib in Myeloma Cells and Overcomes Bortezomib and Carfilzomib Resistance

Blood Cancer Journal
OncologyHematology
2013English

Bortezomib for the Treatment of Multiple Myeloma Patients

Health Technology Assessment
MedicineHealth Policy
2009English

Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib

Seminars in Hematology
Hematology
2009English

Intracellular Glutathione Determines Bortezomib Cytotoxicity in Multiple Myeloma Cells

Blood Cancer Journal
OncologyHematology
2016English

Bortezomib Induces Heme Oxygenase-1 Expression in Multiple Myeloma

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2012English

Blood Distribution of Bortezomib and Its Kinetics in Multiple Myeloma Patients

Clinical Biochemistry
MedicineClinical Biochemistry
2014English

Hedgehog and Retinoid Signaling Alters Multiple Myeloma Microenvironment and Generates Bortezomib Resistance

Journal of Clinical Investigation
Medicine
2016English

Bortezomib: The Evidence of Its Clinical Impact in Multiple Myeloma

Core Evidence
MedicineReviewsReferencesPharmacology
2006English

Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Castor)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy